They demonstrated a significant reduction in blood glucose levels by introducing an inactive FoxO1 variant (FoxO1‐∆256) into the hepatic tissue of db/db mice (a common murine model for studying diabetes, obesity, and metabolic disorders, due to a mutation in the leptin receptor gene). This evidence concerns the gene FOXO1 and metabolic disease.